Lixudebart AAV Phase 3 begins
CSL agreed to fund RENAL completion and a planned Phase 3 AAV-RPGN trial. A later pivotal first dose would be distinct from the already signed collaboration.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Private-company classification is explicitly supported by CSL’s October 5, 2026 partnership announcement, which calls Alentis privately held; recheck before activation.
- Collaboration announcement and planned funding do not establish trial activation; protocol/ownership and current outcome must be refreshed.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Planned Phase 3 — date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will a participant receive lixudebart in the planned Phase 3 AAV-RPGN trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.